David R. Bauer
Lawyers

Filters
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2028, 2030, 2032, 2035, 2055 and 2065
GH Research $150 million follow-on offering
We advised GH Research on the offering of shares
Maze Therapeutics $140 million IPO
The shares are listed on Nasdaq
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
InVue sale to ASSA ABLOY
We advised InVue on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition
Windstream $1.4 billion senior secured first-lien notes offering
The high-yield notes are due 2031
Uranium Energy $300 million at-the-market offering
The shares are listed on NYSE American